Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 277

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy

Open access
Mountzios, Giannis, Sun, Longhua, Cho, Byoung Chul, Demirci, Umut, Baka, Sofia, Gümüş, Mahmut, Lugini, Antonio, Zhu, Bo, Yu, Yan, Korantzis, Ippokratis, Han, Ji-Youn, Ciuleanu, Tudor-Eliade, Ahn, Myung-Ju, Rocha, Pedro, Mazières, Julien, Lau, Sally C.M., Schuler, Martin, Blackhall, Fiona, Yoshida, Tatsuya, Owonikoko, Taofeek K., Paz-Ares, Luis, Jiang, Tony, Hamidi, Ali, Gauto, Diana, Recondo, Gonzalo, Rudin, Charles M.·2025·New England Journal of Medicine

Abstract

BACKGROUND: Tarlatamab, a bispecific delta-like ligand 3-directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer. Whether tarlatamab is more effective than chemotherapy in the treatment of patients whose small-cell lung cancer has progressed during or after initial platinum-based chemotherapy is not known. METHODS: We conducted a multinational, phase 3, open-label trial to compare tarlatamab with chemotherapy as second-line treatment in patients with small-cell lung cancer whose disease had progressed during or after platinum-based chemotherapy. Patients were randomly assigned to receive tarlatamab or chemotherapy (topotecan, lurbinectedin, or amrubicin). The primary end point was overall survival. Key secondary end points were investigator-assessed progression-free survival and patient-reported outcomes. Results of the prespecified interim analysis (data-cutoff date, January 29, 2025) are reported. RESULTS: A total of 509 patients were randomly assigned to receive tarlatamab (254 patients) or chemotherapy (255 patients). Treatment with tarlatamab resulted in significantly longer overall survival than chemotherapy (median, 13.6 months [95% confidence interval {CI}, 11.1 to not reached] vs. 8.3 months [95% CI, 7.0 to 10.2]; stratified hazard ratio for death, 0.60; 95% CI, 0.47 to 0.77; P<0.001). Tarlatamab treatment also had a significant benefit with respect to progression-free survival and cancer-related dyspnea and cough as compared with chemotherapy. The incidence of adverse events of grade 3 or higher was lower with tarlatamab than with chemotherapy (54% vs. 80%), as was the incidence of adverse events resulting in treatment discontinuation (5% vs. 12%). CONCLUSIONS: Treatment with tarlatamab led to longer overall survival than chemotherapy among patients with small-cell lung cancer whose disease had progressed during or after platinum-based chemotherapy. (Funded by Amgen; DeLLphi-304 ClinicalTrials.gov number, NCT05740566.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2502099

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Metadata

Authors
Mountzios, G., Sun, L., Cho, B. C., Demirci, U., Baka, S., Gümüş, M., Lugini, A., Zhu, B., Yu, Y., Korantzis, I., Han, J.-Y., Ciuleanu, T.-E., Ahn, M.-J., Rocha, P., Mazières, J., Lau, S. C. M., Schuler, M., Blackhall, F., Yoshida, T., Owonikoko, T. K., Paz-Ares, L., Jiang, T., Hamidi, A., Gauto, D., Recondo, G., & Rudin, C. M.
Venue
New England Journal of Medicine
Published
2025-07-24
Volume
393
Issue
4
Pages
349-361
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4410961676
Cited by
277
References
17
FWCI
101.01
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy. https://app.cochat.ai/papers/10.1056/nejmoa2502099
The paper
Mountzios, G., Sun, L., Cho, B. C., Demirci, U., Baka, S., Gümüş, M., Lugini, A., Zhu, B., Yu, Y., Korantzis, I., Han, J.-Y., Ciuleanu, T.-E., Ahn, M.-J., Rocha, P., Mazières, J., Lau, S. C. M., Schuler, M., Blackhall, F., Yoshida, T., . . . Rudin, C. M. (2025). Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2502099

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.